NOMIOS-GROUP
2.3.2023 06:33:06 CET | Business Wire | Press release
Nomios Group, a leading European provider of cybersecurity services and solutions, announced today that it has completed the acquisition of a majority stake in Aditinet, a prominent cybersecurity company in the Italian market. The acquisition strengthens Nomios’ European position as one of the leading cybersecurity service companies.
“This acquisition marks an important step in Nomios’ continued growth and success, and we see many benefits in terms of a shared vendor portfolio, customer relationship, and service offerings. Not only does the acquisition of Aditinet provide the Nomios Group with a significant expertise and strong customer base in Italy, but it also allows us to add new services such as ethical hacking to our portfolio” explained Sébastien Kher, CEO of Nomios Group.
With the addition of Aditinet, the Nomios Group annual revenue grows to EUR 400M, and its consolidated headcount grows to over 600 FTEs throughout its seven European markets. The current CEO and Founder (Paolo Marsella) and CFO (Alberto Mez) will remain minority shareholders and will continue to manage the company and will lead the integration within the Nomios Group.
“Becoming part of Nomios is the ideal next step in realising Aditinet’s vision of making IT and the cloud the most secure environment for our customers and in further consolidating our relationships with critical vendors” said Paolo Marsella, CEO of Aditinet. “Nomios will provide European scale and expertise to further accelerate our growth in the Italian market. We look forward to immediately take advantage of Nomios’ famous SOC capabilities to help monitor our customer’s security perimeters and rely on their many references in SASE. We see a lot of talks about these technologies in the market, and our new Nomios colleagues have already proven that they can deliver in both respects”.
About Nomios Group
Nomios is a leading European provider of cybersecurity and secure networking solutions and services and has a broad customer base in highly diversified sectors. In 19 years, Nomios has grown into an organisation with more than 20 offices in seven European countries and has continuously expanded its own professional services, managed services, support and SOC offering. Nomios has the most experienced, loyal and highly certified pool of engineers in its industry, as recognised by many third-party studies, and has strategic partnerships with leading technology providers, including Palo Alto Networks, Juniper Networks, Cisco, Fortinet, F5, and others. In January 2019, funds advised by IK Partners, a leading Pan-European private equity firm, acquired a majority stake in Nomios Group.
About Aditinet
Founded in 2004, Aditinet is an Italian system integration and professional services company specialising in cybersecurity. With an annual revenue of EUR 40 million, Aditinet is among the most recognised players in the Italian cybersecurity industry with best-in- class certifications with Palo Alto Networks (Diamond) and F5 (Platinum) among other highly ranked vendor partnerships. Aditinet has two main offices in Italy, namely in Rome and Milan. Aditinet serves over 150 customers, which include several Italian national banks, utility providers, universities, manufacturing companies and ministries.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230228006051/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom